Search Results

Early Clinical Results Presented for Reva's ReZolve2 Bioresorbable Scaffold

October 28, 2013—Reva Medical, Inc. (San Diego, CA) announced that initial results from the clinical investigation of patients treated with the company's ReZolve2 sirolimus-eluting bioresorbable coronary scaffold were presented at the TCT 2013: Transcatheter Cardiovascular Therapeutics conference in San Francisco, California.

Elixir Medical Announces 2-Year Results From the EXCELLA BD Trial on the Desyne BD System



May 24, 2013—Elixir Medical Corporation (Sunnyvale, CA) announced the long-term results of its CE Mark-approved Desyne BD novolimus-eluting coronary stent system with biodegradable polymer coating compared to the control device, the Endeavor zotarolimus-eluting coronary stent system (Medtronic, Inc., Minneapolis, MN) with durable coating, in the EXCELLA BD randomized clinical trial.

HeartFlow’s FFRct Analysis Will Be Studied in FUSION Trial to Reduce Unnecessary ICA

September 2, 2021—HeartFlow, Inc. announced that physicians at Erasmus MC Hospital in Rotterdam, the Netherlands, have enrolled the first three patients in the FUSION randomized controlled trial.